CARIS LIFE SCIENCES, INC. Selling and Marketing Expense
CARIS LIFE SCIENCES, INC. (CAI) reported Selling and Marketing Expense of $53.76 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:SellingAndMarketingExpense · last filed 2026-08-05
- CARIS LIFE SCIENCES, INC. selling and marketing expense for the quarter ending 2026-06-30 was $53.76M, a 27.22% increase year-over-year.
- CARIS LIFE SCIENCES, INC. selling and marketing expense for the quarter ending 2026-03-31 was $45.04M, a 13.09% increase year-over-year.
- CARIS LIFE SCIENCES, INC. selling and marketing expense for the quarter ending 2025-12-31 was $44.15M, a 17.66% increase year-over-year.
- CARIS LIFE SCIENCES, INC. selling and marketing expense for the quarter ending 2025-09-30 was $41.27M, a 12.27% increase year-over-year.
- CARIS LIFE SCIENCES, INC. selling and marketing expense for fiscal 2025 was $167.51M, a 9.77% increase from fiscal 2024.
- CARIS LIFE SCIENCES, INC. selling and marketing expense for fiscal 2024 was $152.60M, a 6.77% increase from fiscal 2023.
- CARIS LIFE SCIENCES, INC. selling and marketing expense for fiscal 2023 was $142.93M.
| Period end | Selling and Marketing Expense 3 month | Selling and Marketing Expense 6 month | Selling and Marketing Expense 9 month | Selling and Marketing Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $53.76M 10-Q · filed 2026-08-05 | $98.81M 10-Q · filed 2026-08-05 | $142.96M derived: sum of 3 quarters · filed 2026-08-05 | $184.22M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $45.04M 10-Q · filed 2026-05-08 | $89.19M derived: sum of 2 quarters · filed 2026-05-08 | $130.46M derived: sum of 3 quarters · filed 2026-05-08 | $172.72M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $44.15M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $85.42M derived: sum of 2 quarters · filed 2026-03-03 | $127.68M derived: sum of 3 quarters · filed 2026-08-05 | $167.51M 10-K · filed 2026-03-03 |
| 2025-09-30 | $41.27M 10-Q · filed 2025-11-05 | $83.53M derived: sum of 2 quarters · filed 2026-08-05 | $123.36M 10-Q · filed 2025-11-05 | $160.88M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $42.26M 10-Q · filed 2026-08-05 | $82.09M 10-Q · filed 2026-08-05 | $119.61M derived: sum of 3 quarters · filed 2026-08-05 | $156.37M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $39.83M 10-Q · filed 2026-05-08 | $77.35M derived: sum of 2 quarters · filed 2026-05-08 | $114.11M derived: sum of 3 quarters · filed 2026-05-08 | $152.82M derived: sum of 4 quarters · filed 2026-05-08 |
| 2024-12-31 | $37.52M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $74.28M derived: sum of 2 quarters · filed 2026-03-03 | $112.99M derived: sum of 3 quarters · filed 2026-03-03 | $152.60M 10-K · filed 2026-03-03 |
| 2024-09-30 | $36.76M 10-Q · filed 2025-11-05 | $75.47M derived: sum of 2 quarters · filed 2025-11-05 | $115.08M 10-Q · filed 2025-11-05 | |
| 2024-06-30 | $38.71M 10-Q · filed 2025-08-12 | $78.32M 10-Q · filed 2025-08-12 | ||
| 2023-12-31 | $142.93M 10-K · filed 2026-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RadNet, Inc. (RDNT) | United States | $5.611B | -229.65 |
| GRAIL, Inc. (GRAL) | United States | $5.591B | -7.78 |
| VERACYTE, INC. (VCYT) | United States | $3.904B | 41.21 |
| Celcuity Inc. (CELC) | United States | $3.887B | -22.62 |
| CareDx, Inc. (CDNA) | United States | $3.174B | 13.21 |
| Fortrea Holdings Inc. (FTRE) | United States | $1.903B | -19.43 |
| Personalis, Inc. (PSNL) | United States | $1.769B | -13.30 |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |